Thromboxane A2 facilitates IL-17A production from V?4+ ?? T cells and promotes psoriatic dermatitis in mice - 04/08/18
Doi : 10.1016/j.jaci.2018.01.054
Yuri Ueharaguchi, MD a, Tetsuya Honda, MD, PhD a, b 
, Nobuhiro Kusuba, MD a, Sho Hanakawa, MSc a, Akimasa Adachi, MD a, Yu Sawada, MD, PhD a, Atsushi Otsuka, MD, PhD a, Akihiko Kitoh, MD, PhD a, Teruki Dainichi, MD, PhD a, Gyohei Egawa, MD, PhD a, Chisa Nakashima, MD, PhD a, Saeko Nakajima, MD, PhD a, Teruasa Murata, MD, PhD a, Sachiko Ono, MD, PhD a, Makoto Arita, PhD c, d, Shuh Narumiya, MD, PhD b, e, Yoshiki Miyachi, MD, PhD a, Kenji Kabashima, MD, PhD a, f
, Nobuhiro Kusuba, MD a, Sho Hanakawa, MSc a, Akimasa Adachi, MD a, Yu Sawada, MD, PhD a, Atsushi Otsuka, MD, PhD a, Akihiko Kitoh, MD, PhD a, Teruki Dainichi, MD, PhD a, Gyohei Egawa, MD, PhD a, Chisa Nakashima, MD, PhD a, Saeko Nakajima, MD, PhD a, Teruasa Murata, MD, PhD a, Sachiko Ono, MD, PhD a, Makoto Arita, PhD c, d, Shuh Narumiya, MD, PhD b, e, Yoshiki Miyachi, MD, PhD a, Kenji Kabashima, MD, PhD a, f a Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
b Department of Innovation, Center for Immunoregulation Technologies and Drugs, Kyoto University Graduate School of Medicine, Kyoto, Japan
c Laboratory for Metabolomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan
d Division of Physiological Chemistry and Metabolism, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan
e Department of Drug Discovery Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
f Singapore Immunology Network (SIgN) and Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), Singapore
| This work was supported by grants from Special Coordination Funds by the Ministry of Education, Culture, Sports, Science and Technology of Japan and Astellas Pharma Inc in the Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program (T.H.), Japan Society for the Promotion of Science KAKENHI (grant nos. JP15K09766, JP15H05096 [T.H.], and 263395 [K.K.]), Grants-in-Aid for Scientific Research (grant nos. 15H05790, 15H1155, 15K15417 [K.K.], JP15H05897, 15H05898, and 15H04648 [M.A]), Japan Science, and Japan Agency for Medical Research and Development (AMED) (grant nos. 16ek0410011h0003 and 16he0902003h0002 [K.K.], and JP17ek0410040 [S.N.]). |
|
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
© 2018
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 142 - N° 2
P. 680 - août 2018 Retour au numéro
Article précédent
- Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season
- Alexander Kettner, Gilles DellaCorte, Fréderic de Blay, Lars Jacobsen, Marek Jutel, Margitta Worm, Vincent Charlon, Kim Simonsen, Christophe Reymond, François Spertini
- Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus–induced type 2 responses and immunopathology
- Melissa H. Bloodworth, Mark Rusznak, Connor C. Pfister, Jian Zhang, Lisa Bastarache, Sandra Alvarez Calvillo, James D. Chappell, Kelli L. Boyd, Shinji Toki, Dawn C. Newcomb, Matthew T. Stier, Weisong Zhou, Kasia Goleniewska, Martin L. Moore, Tina V. Hartert, Kevin D. Niswender, R. Stokes Peebles
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?